<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04132063</url>
  </required_header>
  <id_info>
    <org_study_id>2018/PY119</org_study_id>
    <nct_id>NCT04132063</nct_id>
  </id_info>
  <brief_title>Generic Substitution of Original Levetiracetam in Thai Epilepsy Patients</brief_title>
  <official_title>Efficacy and Safety of Generic Substitution of Original Levetiracetam in Patients With Epilepsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The retrospective pre-post observational study was conducted to evaluate the real-world
      evidence of efficacy and tolerability of generic levetiracetam (oral tablet) which was
      switched from original levetiracetam (oral tablet) in patients with epilepsy at the national
      hospital for neurology and neurosurgery in Thailand. Epilepsy patients who received generic
      substitution to original levetiracetam at the same dose and had stable conditions of seizure
      were only included. In the period of 6 months, the investigators assessed the change of
      seizure frequency, the incidence of hospitalization due to breakthrough seizure, the
      incidence of adverse events and the incidence of composite outcomes related to dosage
      adjustment of antiepileptic drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2018</start_date>
  <completion_date type="Actual">May 30, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline seizure frequency</measure>
    <time_frame>At baseline, 3 and 6 months after generic levetiracetam substitution</time_frame>
    <description>Change from baseline seizure frequency per month at 3 and 6 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hospitalization</measure>
    <time_frame>During 6 months of generic levetiracetam substitution</time_frame>
    <description>Incidence of hospitalization due to breakthrough seizure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>During 6 months of generic levetiracetam substitution</time_frame>
    <description>Incidence of adverse events after generic levetiracetam substitution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite outcomes</measure>
    <time_frame>During 6 months of generic levetiracetam substitution</time_frame>
    <description>Incidence of composite outcomes related to dosage adjustment of antiepileptic drugs such as
Switching back to original levetiracetam due to experiencing an uncontrolled seizure or adverse drug reactions,
The incremental dose of generic levetiracetam due to experiencing an uncontrolled seizure,
The decremental dose of generic levetiracetam due to experiencing adverse events,
Add-on other antiepileptic drugs due to experiencing an uncontrolled seizure,
The incremental dose of concurrent antiepileptic drugs due to experiencing an uncontrolled seizure.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">75</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Generic levetiracetam</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Generic levetiracetam</intervention_name>
    <description>Generic levetiracetam tablet as the same dose as original levetiracetam tablet at the switching date</description>
    <arm_group_label>Generic levetiracetam</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any epileptic patients who received generic substitution to original levetiracetam from
        February 2016 to May 2018
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of epilepsy for at least 6 months prior to generic levetiracetam
             substitution;

          -  Same dosage form and strength of generic substitution to original levetiracetam;

          -  Stable dose of original levetiracetam and stable seizure frequency prior to generic
             levetiracetam substitution;

          -  Stable dose of generic levetiracetam after generic levetiracetam substitution

        Exclusion Criteria:

          -  Absence seizure with levetiracetam monotherapy;

          -  Original levetiracetam in dosage form of oral solution or intravenous solution prior
             to generic levetiracetam substitution;

          -  Poor compliance;

          -  Death or loss of follow up;

          -  Unavailable data for evaluation of outcomes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jannapas Tharavichitkun</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prasat Neurological Institute</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 15, 2019</study_first_submitted>
  <study_first_submitted_qc>October 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2019</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Generic</keyword>
  <keyword>Levetiracetam</keyword>
  <keyword>Therapeutic equivalency</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levetiracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

